Findings

What do systematic reviews say?

50 questions · 50 findings · 13 reviews · Neuromuscular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 13 · 26%GRADE not reported 16 · 32%Very low 7 · 14%Low 7 · 14%Moderate 6 · 12%High 1 · 2%

Local corticosteroid injection (LCI) vs saline no treatment or placebo

Improvement in quality of life · carpal tunnel syndrome

1 finding from 1 review

Local corticosteroid injection versus placebo for carpal tunnel syndrome 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 111 participants
Moderate

Dextromethorphan and quinidine sulfate combination (DMQ) vs placebo

Quality of life · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Scopolamine (hyoscine) patches vs placebo

Quality of life · people with motor neuron disease/amyotrophic lateral sclerosis with sialorrhea (excessive saliva) (all fed via gastrostomy and most…

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Fludrocortisone vs placebo

Quality of life · people with diabetes and orthostatic hypotension

1 finding from 1 review

Fludrocortisone for orthostatic hypotension 2021 · Cochrane Headline outcomes only
no estimate extracted
0 participants
GRADE not reported

Oral gabapentin vs placebo

Change in quality of life · adults with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 67 participants
Low

Oral hydroxyurea vs placebo

Change in quality of life · children and adults with SMA types II and III

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral olesoxime vs placebo

Change in quality of life · non‐ambulatory children and adolescents with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 108 participants
Low

Oral creatine vs placebo

Change in quality of life · children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 38 participants
Low

Oral phenylbutyrate vs placebo

Change in quality of life · children with SMA type II

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Subcutaneous somatotropin vs placebo

Change in quality of life · children and adults with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
19 participants
Very low

Intravenous thyrotropin releasing hormone vs placebo

Change in quality of life · children with SMA types II and III

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral valproic acid plus acetyl‐L‐carnitine vs placebo

Change in quality of life · non‐ambulatory children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 54 participants
Very low

Oral valproic acid vs placebo

Change in quality of life · ambulatory adults with SMA type III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
28 participants
Moderate

Calf stretching vs placebo stretching

Health‐related quality of life · older adults with lower limb muscle cramps

The review found no eligible studies for this question.

1 finding from 1 review

Non‐drug therapies for the secondary prevention of lower limb muscle cramps 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Idebenone vs placebo

Improvements in quality of life measures · boys (aged 8 to 16 years old) with subclinical cardiomyopathy in DMD

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X‐linked… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Eplerenone (25 mg daily) vs placebo

Improvements in quality of life measures · boys with DMD and left ventricular ejection fraction 45% or more

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X‐linked… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Growth hormone (0.23 mg/kg/week for DMD and 0.07 mg/kg/week in BMD SC injection) vs placebo

Improvements in quality of life measures · people with DMD or BMD (ages not stated)

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X‐linked… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Prophylactic perindopril (2 mg to 4 mg daily) vs placebo

Improvements in quality of life measures · boys with DMD, normal cardiac examination and LVEF > 55% at baseline

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X‐linked… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Alpha‐lipoic acid vs placebo

Change in any validated quality of life score · people with DPN

The review found no eligible studies for this question.

1 finding from 1 review

Alpha‐lipoic acid for diabetic peripheral neuropathy 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Thyrotropin‐releasing hormone tartrate vs placebo

Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported